The abbott realtime high risk HPV test is a clinically validated human papillomavirus assay for triage in the referral population and use in primary cervical cancer screening in women 30 years and older: A review of validation studies

Acta Dermatovenerologica Alpina, Pannonica et Adriatica

Volumn 22, Issue 2, 2013, Pages 43-47

  Poljak, Mario ^a   Ostrbenk, Anja ^a  

^a UNIVERSITY OF LJUBLJANA   (Slovenia)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; BIOASSAY; CANCER SCREENING; CLINICAL ARTICLE; CLINICAL EVALUATION; CLINICAL PRACTICE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; EMERGENCY HEALTH SERVICE; EUROPE; FEMALE; GENOTYPE; HIGH RISK PATIENT; HUMAN; HUMAN CELL; HUMAN PAPILLOMAVIRUS TEST; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; MEDICAL LITERATURE; PATIENT REFERRAL; POPULATION; PRECANCER; PRIMARY HEALTH CARE; PUBLISHING; REAL TIME POLYMERASE CHAIN REACTION; REVIEW; SENSITIVITY AND SPECIFICITY; SERODIAGNOSIS; UTERINE CERVIX CANCER; VALIDATION STUDY;

ADULT; AGE FACTORS; DNA PROBES, HPV; DNA, VIRAL; EARLY DETECTION OF CANCER; FEMALE; HUMAN PAPILLOMAVIRUS 16; HUMAN PAPILLOMAVIRUS 18; HUMANS; MIDDLE AGED; PAPILLOMAVIRUS INFECTIONS; REAL-TIME POLYMERASE CHAIN REACTION; REFERRAL AND CONSULTATION; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SLOVENIA; TRIAGE; UTERINE CERVICAL NEOPLASMS;

EID: 84880759344     PISSN: 13184458     EISSN: None     Source Type: Journal    
DOI: 10.2478/v10162-012-0031-2     Document Type: Review

References (32)

1. Arbyn M, Castellsague X, de Sanjose S, Bruni L, Saraiya M, Bray F, et al. Worldwide burden of cervical cancer in 2008. Ann Oncol. 2011;22:2675-86.
2. Poljak M, Cuzick J, Kocjan BJ, IftnerT, Dillner J, Arbyn M. Nucleic acid tests for the detection of alpha human papillomaviruses. Vaccine. 2012;30(Suppl 5):F100-6.
3. Cox JT. History of the use of HPV testing in cervical screening and in the management of abnormal cervical screening results, j Clin Virol. 2009;45(Suppl 1):S3-12.
4. Cuschieri KS, Cubie HA. The role of human papillomavirus testing in cervical screening. J Clin Virol. 2005;32(Suppl 1):S34-S42.
5. Arbyn M, Ronco B, Anttila A, Meijer CJ, Poljak M, Ogilvie G, et al. Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer. Vaccine. 2012;30(Suppl 5):F88-F99.
6. Arbyn M, Ronco G, Cuzick J, Wentzensen N, Castle PE. How to evaluate emerging technologies in cervical cancer screening? Int J Cancer. 2009;125:2489-96.
7. Poljak M, Kocjan BJ. Commercially available assays for multiplex detection of alpha human papillomaviruses. Exp RevAnti Infect Ther. 2010;8:1139-62.
8. Khan MJ, Castle PE, Lorincz AT, Wacholder S, Sherman M, Scott DR, et al. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice.J Natl Cancer Inst. 2005;97:1072-9.
9. Huang S, Tang N, Mak WB, Erickson B, Salituro j, Li Y, et al. Principles and analytical performance of Abbott RealTime High Risk HPV test. J Clin Virol. 2009;45(Suppl 1):S13-S7.
10. Poljak M, Kovanda A, Kocjan BJ, Seme K, lancar N, Vrtacnik-Bokal E. The Abbott RealTime High Risk HPV test: comparative evaluation of analytical specificity and clinical sensitivity for cervical carcinoma and CIN 3 lesions with the Hybrid Capture 2 HPV DNA test. Acta Dermatovenerol Alp Panonica Adriat. 2009:18:94- 103.
11. Kocjan BJ, Maver PJ, Hosnjak L, Zidar N, Odar K, Gale N, et al. Comparative evaluation of the Abbott RealTime High Risk HPV test and INNO-LiPA HPV Genotyping Extra test for detecting and identifying human papillomaviruses in archival tissue specimens of head and neck cancers. Acta Dermatovenerol Alp Panonica Adriat. 2012;21:73-5.
12. Kocjan BJ, Seme K, Poljak M. Comparison of the Abbott RealTime High Risk HPV test and INNO-LiPA HPV Genotyping Extra test for the detection of human papillomaviruses in formalin-fixed, paraffin-embedded cervical cancer specimens. J Virol Methods. 2011;175:117-9.
13. Snietura M, Jaworska M, Piglowski W, Goraj-Zajac A, Wozniak G, Lange D. High risk HPV DNA status and pi6 (INKa) expression as prognostic markers in patients with squamous cell cancer of oral cavity and oropharynx. Pol J Pathol. 2010;61:133-9.
14. Snietura M, Piglowski W, jaworska M, Mucha-Matecka A, Wozniak G, Lange D, et al. Impact of HPV infection on the clinical outcome of p-CAIR trial in head and neck cancer. Eur Arch Otorhinolaryngol. 2011;268:721-6.
15. Poljak M, Ostrbenk A, Seme K, Ucakar V, Hillemanns P, Bokal EV, et al. Comparison of clinical and analytical performance of the Abbott Realtime High Risk HPV test to the performance of Hybrid Capture 2 in population-based cervical cancer screening, j Clin Microbiol. 2011;49:1721-9.
16. Carozzi FM, Burroni E, Bisanzi S, Puliti D, Confortini M, Giorgi Rossi P, et al. Comparison of clinical performance of Abbott RealTime High Risk HPV test with that of Hybrid Capture 2 assay in a screening setting, j Clin Microbiol. 2011;49:1446-51.
17. Halfon P, Benmoura O, Agostini A, Khiri H, Penaranda G, Martineau A, et al. Evaluation of the clinical performance of the Abbott RealTime High-Risk HPV for carcinogenic HPV detection. J Clin Virol. 2010;48:246-50.
18. Venturoli S, Leo E, Nocera M, Barbieri D, Cricca M, Costa S, et al. Comparison of Abbott Real Time High Risk HPV and Hybrid Capture 2 for the detection of high- risk HPV DNA in a referral population setting. J Clin Virol. 2012;53:121-4.
19. jentschke M, Soergel P, Lange V, Kocjan B, Doerk T, Luyten A, et al. Evaluation of a new multiplex real-time polymerase chain reaction assay for the detection of human papillomavirus infections in a referral population. Int j Gynecol Cancer. 2012;22:1050-6.
20. Park Y, Lee E, Choi I, jeong S, Kim HS. Comparison of the Abbott RealTime High-Risk Human Papillomavirus (HPV), Roche Cobas HPV, and Hybrid Capture 2 assays to direct sequencing and genotyping of HPV DNA. J Clin Microbiol. 2012;50:2359-65.
21. Hwang Y, Lee M. Comparison of the AdvanSure human papillomavirus screening real-time PCR, the Abbott RealTime High Risk human papillomavirus test, and the Hybrid Capture human papillomavirus DNA test for the detection of human papillomavirus. Ann Lab Med. 2012;32:201-5.
22. Tang N, Huang S, Erickson B, Mak WB, Salituro I, Robinson J, et al. High-risk HPV detection and concurrent HPV 16 and 18 typing with Abbott RealTime High Risk HPV test. J Clin Virol. 2009;45(Suppl 1):S25-s8.
23. Kovanda A, Juvan U, Sterbenc A, Kocjan BJ, Seme K, lancar N, et al. Pre-vacci- nation distribution of human papillomavirus (HPV) genotypes in women with cervical intraepithelial neoplasia grade 3 (CIN 3) lesions in Slovenia. Acta Dermatovenerol Alp Panonica Adriat. 2009;18:47-52.
24. Huang S, Erickson B, Tang N, Mak WB, Salituro I, Robinson j, et al. Clinical performance of Abbott RealTime High Risk HPV test for detection of high-grade cervical intraepithelial neoplasia in women with abnormal cytology. J Clin Virol. 2009;45(Suppl 1):S19-S23.
25. Cuzick I, Ambroisine L, Cadman L, Austin J, Ho L, Terry G, et al. Performance of the Abbott RealTime high-risk HPV test in women with abnormal cervical cytology smears. j Med Virol. 2010;82:1186-91.
26. Halfon P, Benmoura D, Agostini A, Khiri H, Penaranda G, Martineau A, et al. Stepwise algorithm combining HPV high-risk DNA-based assays and RNA-based assay for high grade CIN in women with abnormal smears referred to colposcopy. Cancer Biomark. 2010;7:133-9.
27. Wong OG, Lo CK, Szeto E, Cheung AN. Efficacy of Abbott RealTime High Risk HPV test in evaluation of atypical squamous cells of undetermined significance from an Asian screening population. J Clin Virol. 2011;51:136-8.
28. Szarewski A, Mesher D, Cadman L, Austin j, Ashdown-Barr L, Ho L, et al. Comparison of seven tests for high-grade cervical intraepithelial neoplasia in women with abnormal smears: the Predictors 2 study. I Clin Microbiol. 2012;50:1867-73.
29. Mesher D, Szarewski A, Cadman L, Austin I, Ashdown-Barr L, Ho L, et al. Comparison of human papillomavirus testing strategies for triage of women referred with low-grade cytological abnormalities. Eur J Cancer. 2013 (in press).
30. Hesselink AT, Meijer C), Poljak M, Berkhof J, van Kemenade FJ, van der Salm ML, et al. Clinical validation of the Abbott RealTime High Risk HPV assay according to the guidelines for HPV DNA test requirements for cervical screening. J Clin Microbiol. 2013 (in press).
31. Cuzick I, Cadman L, Mesher D, Austin I, Ashdown-Barr L, Ho L, et al. Comparing the performance of six human papillomavirus tests in a screening population. Br J Cancer. 2013;108:908-13.
32. Meijer CJ, Berkhof J, Castle PE, Hesselink AT, Franco EL, Ronco G, et al. Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older. Int j Cancer. 2009;124:516-20.